Beijing Wantai plans large trial for nasal spray COVID-19 vaccine candidate

Chinese vaccine developer Beijing Wantai Biological Pharmacy Enterprise plans to start a large trial for its nasal spray-based COVID-19 vaccine candidate next month, a clinical trial registration record showed. The company aims to recruit 40,000 adult participants for the Phase III clinical trial, according to an entry posted on the Chinese Clinical Trial Registry on Wednesday